RESPOND PRESENTATIONS 2024


Conference on Retrovirus and Opportunistic Infections (CROI 2024), Denver, Colorado, USA, 3-6 March 2024.

Poster presentation:
Temporal Trends of Cardiovascular Disease Incidence in People with HIV from 2001-2021 presented by Nadine Jaschinski on behalf of the RESPOND Study Group.POSTER  


Poster presentation:
Increased Cancer Risk With Low CD4 Counts Persists Despite Over 2 Years of Virological Suppression   presented by Jennifer Hoy on behalf of the RESPOND Study Group.POSTER

 

The 25th International AIDS conference (IAS) 22-26 July 2024.

Oral presentation:

Detailed modeling of viremia exposure does not independently predict cardiovascular diseases in people with HIV, presented by Olof Elvstam on behalf of the RESPOND Study Group.PRESENTATION

  •  

Australasian HIV & AIDS conference (ASHM), Sydney, Australia, 16-18 September 2024.

Oral presentation:

Risk of cancer in people with HIV with poor immune recovery despite sustained virological suppression for more than two years on effective antiretroviral treatment, presented by Win Min Han on behalf of the RESPOND Study Group.PRESENTATION 


HIV&Virology Nordic Conference, Stockholm, Sweden, 25-27 September 2024.

Poster presentation:

RESPONDing to Contemporary Challenges for People Living with HIV: An Envolving Cohort Collaboration, presented by Bastian Neesgaard on behalf of the RESPOND Study Group.POSTER 


HIV Drug Therapy Glasgow 2024, Glasgow, Great Britain, 10-13 November 2024.

Poster presentation: 
Outcomes after the most common cancers in people with HIV  presented by Alisa Timiryasova on behalf of the RESPOND  and D:A:D  study groups.

Poster presentation:
Mortality using raltegravir versus other integrase inhibitors in people with HIV in Europe and Australia  presented by Erich Tusch on behalf of the RESPOND study group.

Poster presentation:
Prevalence of HIV drug resistance in people newly diagnosed with HIV who have used pre-exposure prophylaxis in Europe: the PrEPaRE study,  presented by Valentina Cambiano on behalf of the RESPOND study group.
 

 

CROI 2025, San Francisco, USA, 9-12 March 2025

Accepted for poster presentation: 
Cancer Incidence in Women With HIV in Europe and Australia: A Combined D:A:D and Respond Analysis will be presented by  Win Min Han on behalf of the RESPOND  and D:A:D  study groups.

Accepted for poster presentation:
Determinants of Steatotic Liver Disease Among People With HIV in Europe and Australia will be presented by Carlotta Riebensahm on behalf of the RESPOND study group.